Skip to main content

PAPAVERINE HYDROCHLORIDE

Generic: Papaverine Hydrochloride

Verified·Apr 23, 2026
NDC
54288-142
ICD-10 indication
I73.9

Affordability Check

How much will you actually pay for PAPAVERINE HYDROCHLORIDE?

In 30 seconds, see every legitimate way to afford PAPAVERINE HYDROCHLORIDE — Medicare copay, manufacturer copay card, Patient Assistance Program, grants, or cash.

Check my options →

About PAPAVERINE HYDROCHLORIDE

What is this medication? Papaverine hydrochloride is a vasodilator that functions by relaxing smooth muscles throughout the body, particularly those within the walls of blood vessels. By encouraging these vessels to dilate, the medication helps to increase blood flow and reduce the pressure within the circulatory system. It is commonly used to treat conditions characterized by vascular spasms, such as those occurring in the heart or brain, and it can help manage complications from peripheral vascular disease by improving circulation to the limbs. In addition to its use for blood vessel issues, this medication is also employed to relieve spasms in the smooth muscles of the gastrointestinal tract, the gallbladder, and the urinary system. It works directly on the muscle cells to stop contractions that cause pain and discomfort. Physicians may also utilize papaverine hydrochloride during certain surgical procedures or to treat specific types of ischemia where localized blood flow needs to be restored quickly to prevent tissue damage.

Copay & patient assistance

Detailed copay and financial assistance information is not publicly available for this medication at this time. Please consult your pharmacist or the manufacturer's official patient support program for more details.

External links go directly to the manufacturer's portal. RxCopays does not receive compensation for referrals.

Compare pricing elsewhere

RxCopays doesn't sell drugs or take referral fees. Here are the transparent-pricing directories we recommend checking alongside your insurance formulary.

We deep-link because transparency helps patients. None of these partners pay RxCopays.

Prescribing information

From the FDA-approved label for PAPAVERINE HYDROCHLORIDE. Official source: DailyMed (NLM) · Label effective Dec 26, 2025

Indications and usage
INDICATIONS AND USAGE Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states, and visceral spasm , as in ureteral, biliary, or gastrointestinal colic.
Dosage and administration
DOSAGE AND ADMINISTRATION Papaverine Hydrochloride may be administered intravenously or intramuscularly. The intravenous route is recommended when an immediate effect is desired, but the drug must be injected slowly over the course of 1 or 2 minutes to avoid uncomfortable or alarming side effects. Parenteral administration of papaverine hydrochloride in doses of 1 to 4 mL is repeated every 3 hours as indicated. In the treatment of cardiac extrasystoles, 2 doses may be given 10 minutes apart.
Contraindications
CONTRAINDICATIONS Intravenous injection of papaverine is contraindicated in the presence of complete atrioventricular heart block. When conduction is depressed, the drug may produce transient ectopic rhythms of ventricular origin, either premature beats or paroxysmal tachycardia. Papaverine Hydrochloride is not indicated for the treatment of impotence by intracorporeal injection. The intracorporeal injection of papaverine hydrochloride has been reported to have resulted in persistent priapism requiring medical and surgical intervention.
Adverse reactions
ADVERSE REACTIONS The following side effects have been reported: general discomfort, nausea, abdominal discomfort, anorexia, constipation or diarrhea, skin rash, malaise, vertigo, headache, intensive flushing of the face, perspiration, increase in the depth of respiration, increase in heart rate, a slight rise in blood pressure, and excessive sedation. Hepatitis, probably related to an immune mechanism, has been reported infrequently. Rarely, this has progressed to cirrhosis. To report SUSPECTED ADVERSE REACTIONS, contact BPI Labs, LLC at (727) 471-0850 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Use in pregnancy
Pregnancy Pregnancy Category C - No teratogenic effects were observed in rats when papaverine hydrochloride was administered subcutaneously as a single agent. It is not known whether papaverine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Papaverine Hydrochloride should be given to a pregnant woman only if clearly needed.

Label text is reproduced as-is from the FDA-approved label. We do not paraphrase, summarize, or omit. Content above is for informational purposes only and is not medical advice. Always consult your prescribing clinician or pharmacist before making decisions about your medication.

Conditions we've indexed resources for

Click a condition to see copay cards, grants, and PA rules specific to it. For the full list of FDA-approved indications, see Prescribing information above.

Prior authorization & coverage

PayerPAStep therapyCopay tier

Medicare Part D

Medicare Part D

Related drugs

How this page is sourced

  • Drug identity verified against openFDA NDC Directory.
  • Label text (when shown) originates from NLM DailyMed.
  • Copay and assistance URLs verified periodically; if you hit a broken link, tell us.